Actavis' Women Health Biz Update - Analyst Blog


Shutterstock photo

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. Consequently, pipeline-related setbacks have the potential to put a stock behind the pack.

Last week, Actavis plc ( ACT ) suffered a setback when the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for the New Drug Application (NDA) of its oral contraceptive candidate. The company is looking to get its progestin-only transdermal contraceptive patch (norethindrone transdermal delivery system) approved for the prevention of pregnancy.

The U.S. regulatory body has asked for more data on Actavis' contraceptive patch. The FDA raised questions primarily on the differences in size and formulation of the transdermal patch used in the studies and the to-be-marketed product.

Actavis now intends to discuss the issues raised in the CRL with the FDA. The NDA was submitted on Feb 26, 2013, and included data from a 12-month, multi-center, open-label study. The CRL comes as a huge blow to the company's efforts to strengthen its women's health business.

Meanwhile, Actavis filed an Abbreviated New Drug Application (ANDA) for its ethinyl estradiol and etonogestrel vaginal ring with the FDA last week. Ethinyl estradiol and etonogestrel vaginal ring is the generic version of Merck & Co. 's ( MRK ) NuvaRing, which is an estrogen/progestin combination hormonal contraceptive approved for the prevention of pregnancy.

Actavis believes that it is the first to file an ANDA for the generic version of NuvaRing. Consequently, it should enjoy 180 days of marketing exclusivity. As per data released by IMS Health, NuvaRing grossed total U.S. sales of around $560 million for the 12 months ending Oct 31, 2013.

We note that Merck has filed a lawsuit (under the provisions of the Hatch-Waxman Act) against Actavis seeking to prevent the latter from commercializing its generic version of NuvaRing before the expiration of U.S. Patent No 5,989,581.

Actavis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks include Dr. Reddy's Laboratories Ltd. ( RDY ) and Vanda Pharmaceuticals, Inc. ( VNDA ). Both stocks carry a Zacks Rank #1 (Strong Buy).

ACTAVIS PLC (ACT): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

DOCTOR REDDYS (RDY): Free Stock Analysis Report

VANDA PHARMACT (VNDA): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: ACT , CRL , MRK , RDY , VNDA

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by